Skye Bioscience (FRA:09R) ROE % Adjusted to Book Value: -165.57% (As of Mar. 2026)


FRA:09R Skye Bioscience Inc FRA:09R
12 GF Score
Price €0.56
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience ROE % Adjusted to Book Value?

Skye Bioscience FRA:09R -15.91% 12 ROE % Adjusted to Book Value is -165.57% as of Mar. 2026. GuruFocus rates FRA:09R with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Skye Bioscience's ROE % for the quarter that ended in Mar. 2026 was -347.70%. Skye Bioscience's PB Ratio for the quarter that ended in Mar. 2026 was 2.10. Skye Bioscience's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -165.57%.

Skye Bioscience ROE % Adjusted to Book Value Related Terms

Skye Bioscience ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience ROE % Adjusted to Book Value Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -97.67

Skye Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -79.69 -48.32 -38.49 -183.93 -165.57

FRA:09R vs PLRZ, NEUP, LGVN: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Skye Bioscience's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Skye Bioscience ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's ROE % Adjusted to Book Value falls into.


FRA:09R
12GF Score
Skye Bioscience Inc FRA:09R
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience ROE % Adjusted to Book Value Calculation

Skye Bioscience's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-116.23% / 1.19
=-97.67%

Skye Bioscience's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-347.70% / 2.10
=-165.57%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -165.57% mean?
Skye Bioscience (FRA:09R) has a ROE % Adjusted to Book Value of -165.57% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Skye Bioscience and its competitors.
Is Skye Bioscience's ROE % Adjusted to Book Value too high?
Skye Bioscience's current ROE % Adjusted to Book Value is -165.57%. Overall, Skye Bioscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's ROE % Adjusted to Book Value compare to PLRZ and NEUP?
Skye Bioscience's ROE % Adjusted to Book Value of -165.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Skye Bioscience and its competitors. Skye Bioscience's current ROE % Adjusted to Book Value is -165.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current ROE % Adjusted to Book Value of -165.57%. The current ROE % Adjusted to Book Value is -165.57%. Skye Bioscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current ROE % Adjusted to Book Value is -165.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
12GF Score

Get the complete analysis for FRA:09R

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.56
Price